糖心vlog

Skip to content
NOWCAST 糖心vlog News at 10pm Weeknights
Watch on Demand
Advertisement

Iowa's severe COVID-19 outbreak brings experimental drug to state

Iowa's severe COVID-19 outbreak brings experimental drug to state
SOME PROMISING NEWS IN THE PANDEMIC. 糖心vlog HAS LEARNED IOWA WILL BE ONE OF THE FIRST STATES IN THE COUNTRY TO GET A NEW EXPERIMENTAL DRUG TO FIGHT COVID-19. 糖心vlog鈥橲 CYNTHIA FODOR IS LIVE WITH WHY IOWA IS NEAR THE TOP OF THE LIST. >> THE FDA JUST CLEARED EMERGENCY USE OF A NEW EXPERIMENTAL DRUG ON MONDAY. NOW I鈥橫 TOLD HOSPITALS HERE ARE RECEIVING INFORMATION ON HOW TO ADMINISTER IT. IT鈥橲 A SIGN OF HOPE FOR COVID 19 PATIENTS IN IOWA. >> WE鈥橠 LIKE TO SEE MORE DATA BUT ANYTHING THAT鈥橲 POTENTENTIALLY BENEFIFICIAL WE鈥橰E EXCITED ABOUT. >> MERCYONE MEDICAL CENTER IS GEARING UP TO TRY TO FIGHT CORONAVIRUS WITH A DRUG JUST CLEARED BY THE FDA FOR EMERGENCY USE CALLED BAMLANIVIMAB. I鈥橫 TOLD IOWA WILL BE ONE OF THE FIRST STATES TO RECEIVE IT BECAUSE IOWA IS ONE OF THE WORST STATES FOR COVID >> HOSPITALS ARE TOLD WE鈥橪L GET CASE HOSPITALS ARE TOLD WE鈥橪L GET THE AGENT BASED ON CASELOADS IN THE COMMUNITY. IOWA IS NUMBER 3-4 IN CASES PER DAY, SO WE鈥橪L BE GETTING OUR FAIR SHARE OF THIS AGENT. >> MERCYONE INFECTIOUS DISEASE SPECIALIST DR. RAVI VEMURI SAYS THE MONOCLONAL ANTIBODY PRODUCT WILL FOCUS ON PEOPLE WHO ARE AT HIGH RISK WITH MILD TO MODERATE CASES OF COVI >> TAKING THE DRUG WITHIN THE FIRST TEN DAYS OF SYMPTOMS, 70% WHO WOULD GO TO HOSPITAL WILL NOT. >> IT WILL SPECIFICALLY BE USED ON PATIENTS OVER 60 WITH HEART DISEASE, DIABETES, OR OBESITY AND CHILDREN OVER 12 WHO ARE IMMUNOCOMPROMISED. >> THERE鈥橲 POTENTIALLY A HUGE POOL OF PATIENTS WHO FALL UNDER THIS, WE鈥橪L HAVE TO TRIAGE WH GETS IT AND WHO DOESN鈥 >> I鈥橫 TOLD THE DEPARTMENT OF HEALTH WILL DECIDE HOW THE DRUG WILL BE ALLOCATED. THE ELI LILLY CEO SAYS IT IS THE FIRST DRUG EVER IN THE WORLD DESIGNED TO NEUTRALIZE C
Advertisement
Iowa's severe COVID-19 outbreak brings experimental drug to state
Iowa will be among the first states in the country to receive an experimental drug to fight COVID-19.MercyOne Medical Center confirmed Thursday to 糖心vlog that it is receiving information on how to administer bamlanivimab 鈥 a drug cleared for emergency use on Monday by the FDA.MercyOne Infectious disease specialist Dr. Ravi Vemuri said Iowa will receive access to the medication because it has one of the worst COVID-19 outbreaks in the country.鈥淗ospitals are told that we will get the agent based on what kind of caseload we are seeing in our communities,鈥 Vemuri said. 鈥淪o, obviously, Iowa is like no. 3 or 4 in the nation in terms of cases per day. So, I鈥檓 sure we鈥檒l be getting our fair share of this agent.鈥滱ccording to Eli Lilly CEO Dave Ricks, the monoclonal antibody product will be given to patients who are at high risk with mild to moderate cases of COVID-19."Taking this drug within the first 10 days of symptoms, 70% of those people who would have gone to hospital will not,鈥 Ricks said.Vemuri said MercyOne plans to use the medication on patients over 60 with heart disease, diabetes or obesity and children over 12 who are immunocompromised. 鈥淭here's potentially a huge pool of patients that would fall under that indication, and if we get only X amount, you know, we'll have to triage and decide who gets it and who doesn't,鈥 Vemuri said.Ricks said bamlanivimab is the first drug in the world designed to neutralize COVID-19.

Iowa will be among the first states in the country to receive an experimental drug to fight COVID-19.

MercyOne Medical Center confirmed Thursday to 糖心vlog that it is receiving information on how to administer bamlanivimab 鈥 a drug cleared for emergency use on Monday by the FDA.

Advertisement

MercyOne Infectious disease specialist Dr. Ravi Vemuri said Iowa will receive access to the medication because it has one of the worst COVID-19 outbreaks in the country.

鈥淗ospitals are told that we will get the agent based on what kind of caseload we are seeing in our communities,鈥 Vemuri said. 鈥淪o, obviously, Iowa is like no. 3 or 4 in the nation in terms of cases per day. So, I鈥檓 sure we鈥檒l be getting our fair share of this agent.鈥

According to Eli Lilly CEO Dave Ricks, the monoclonal antibody product will be given to patients who are at high risk with mild to moderate cases of COVID-19.

"Taking this drug within the first 10 days of symptoms, 70% of those people who would have gone to hospital will not,鈥 Ricks said.

Vemuri said MercyOne plans to use the medication on patients over 60 with heart disease, diabetes or obesity and children over 12 who are immunocompromised.

鈥淭here's potentially a huge pool of patients that would fall under that indication, and if we get only X amount, you know, we'll have to triage and decide who gets it and who doesn't,鈥 Vemuri said.

Ricks said bamlanivimab is the first drug in the world designed to neutralize COVID-19.